Pfizer Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer (mNSCLC) Tyrosine Kinase Inhibitors (TKI) Therapy
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Friday 17th, April 2026
External Deadline: Wednesday 22nd, April 2026
Description
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: February 4, 2026
Geographic Scope: Canada
Clinical Area: ALK+ Non-Small Cell Lung Cancer (ALK+ NSCLC)
Link to full RFP: 2026 ONC CAN Education ALK+ mNSCLC TKI Therapy IME
Application Due Date: April 22, 2026
Specific Area of Interest: Examples of educational formats that will be considered under this RFP include but are not limited to:
- – Developing educational initiatives that empower patients to identify and actively report ALK TKI-related adverse events, thereby enhancing the accuracy and effectiveness of adverse event management and promoting treatment adherence.
- – Creating podcasts and resources (digital and/or print) for patients and/or the allied healthcare team.
- – Development of educational tools for HCPs and/or patients in a local or regional setting for the management of ALK+ NSCLC patients by multidisciplinary teams.
- Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Ying Ying (Elena) Huang (yingying.huang@pfizer.com).